Skip to main content

J.P. Morgan Remains a Hold on SAGE Therapeutics (SAGE)

Tipranks - Tipranks - Mon Jun 23, 2025

In a report released on June 20, Anupam Rama from J.P. Morgan maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $8.50. The company’s shares closed last Friday at $9.30.

Confident Investing Starts Here:

Rama covers the Healthcare sector, focusing on stocks such as Neurocrine, Sarepta Therapeutics, and Vera Therapeutics. According to TipRanks, Rama has an average return of -6.9% and a 37.70% success rate on recommended stocks.

SAGE Therapeutics has an analyst consensus of Hold, with a price target consensus of $9.04, which is a -2.80% downside from current levels. In a report released on June 20, Robert W. Baird also maintained a Hold rating on the stock with a $9.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $13.47 and a one-year low of $4.62. Currently, SAGE Therapeutics has an average volume of 1.52M.

Read More on SAGE:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).